Related Experiment Video
Updated: Jan 12, 2026

Plasmonic Photothermal Cancer Therapy: Nanoparticle-embedded Tumor-tissue-mimicking Phantoms for Visualizing Photothermal Temperature Distribution
Published on: May 9, 2025
Avenues for integrating photothermal therapy in cancer clinic
Chetna Patnaik1,2, Sulagna Rath1,2, Abhijit De3
1Molecular Functional Imaging Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, India.
Abstract:
Experimental cancer therapeutics are rapidly advancing, with novel approaches emerging to reduce global cancer burden. This review focuses on challenges hindering the clinical integration of photothermal therapy (PTT), despite its therapeutic potential. Key PTT considerations include photothermal agent (PTA), laser properties and strategies for better application, efficacy and precision. Common parameters for PTA evaluation demonstrate biocompatibility, biodistribution and efficacy assessments. However, for clinical emphasis, targeting efficiency and post-therapy fate determination of PTA, sophisticated engineering of photonic devices, precision assessments as well as pain mitigation are critical. Directed future endeavours, keeping these insights, may facilitate application of PTT as a viable cancer treatment in clinical settings.
Insights
Photothermal therapy (PTT) shows promise for cancer treatment but faces clinical integration challenges. Addressing photothermal agent (PTA) targeting, device engineering, and patient comfort is crucial for PTT
Area of Science:
- Oncology
- Biomedical Engineering
- Photomedicine
Background:
- Experimental cancer therapeutics are advancing rapidly.
- Photothermal therapy (PTT) offers therapeutic potential for reducing global cancer burden.
- Clinical integration of PTT faces several challenges.
Purpose of the Study:
- This review focuses on challenges hindering the clinical integration of PTT.
- To identify key considerations for advancing PTT in clinical settings.
Main Methods:
- Review of current literature on PTT.
- Analysis of parameters for photothermal agent (PTA) evaluation.
- Identification of critical factors for clinical translation.
Main Results:
- Common PTA evaluations include biocompatibility, biodistribution, and efficacy.
- Clinical translation requires improved PTA targeting efficiency and fate determination.
- Sophisticated photonic device engineering, precision assessment, and pain mitigation are critical.
Conclusions:
- Addressing PTA behavior, device engineering, and patient experience is vital for PTT clinical application.
- Future research should focus on these critical factors to facilitate PTT as a viable cancer treatment.
More Related Videos
09:01Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
09:23Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods
Published on: October 10, 2025
Related Concept Videos
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers